Skip to main content
. 2023 Apr 1;26(5):106552. doi: 10.1016/j.isci.2023.106552

Figure 2.

Figure 2

UBKO mice exhibit enhanced “browning” of WAT under the β3-adrenergic receptor agonist CL-316,243 administration

(A) The schematic diagram for the 5-day CL-316,243 treatment.

(B) Body weight of UBKO and control male mice (n = 4–5 for each group).

(C and D) H&E staining and immunolabeling for β-catenin and UCP1 of sections of eWAT (C) and iWAT (D) depots from control and UBKO mice. Scale bars, 50 μm (n = 3 for each group).

(E and F) mRNA levels of thermogenic (E) and mitochondrial function-associated (F) genes in the eWAT of UBKO and control male mice. (n = 4–5 for each group).

(H and I) mRNA level of thermogenic (H) and mitochondrial function-associated (I) genes in the iWAT of UBKO and control male mice. (n = 4–5 for each group).

(G and J) Expression of UCP1 protein in the eWAT (G) and iWAT (J) of UBKO and control male mice (20 μg of total protein from tissue lysate was loaded onto gel). WT 0.1 μg BAT lysate and 1 μg BAT lysate were loaded as control of eWAT and iWAT, respectively. (n = 3 for each group). For B–J, 8-week-old UBKO and control male mice were injected with CL-316,243 for 5 days. Data are shown as means ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. See also Figure S3.